Multinational drug giants go for dual in Korean pharmaceutical market

Published: 2007-01-05 07:00:00

Updated: 2007-01-05 07:00:00

This year, competition is about to heat up in the Korean pharmaceutical market as a growing number of new products would be launched by foreign drug makers.

GSK is about to set foot in the market with its newly developed anti-diabetic drug, named Avandaryl (rosiglitazone maleate and glimepirid...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK